GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. Use this tool to calculate the stability of any GSK vaccine. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. The information is not intended as medical advice. Gibbons D, Marijam A, Symons JM, et al. 4. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. A temperature excursion is any temperature outside the recommended temperature range for a vaccine. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. Hwee J, Smith S, Small M, et al. 2. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 1. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Mannino D, Siddall J, Small M, et al. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. 2017;31(2):101-1261. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Discard if the vaccine has been frozen. Silver J, Deb A, Packnett E, et al. You might just need to refresh it. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. 5. 2. 2. 3. This resource may include information that has not been approved by the US Food and Drug Administration. 1. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. Input temperature should be greater than 8.4 C or 47.2 F, Input temperature should be less than 1.5 C or 34.7 F, ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. Genes Dev. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. 2013;62(4):773-785. Desrosiers M, Diamant Z, Castelnuovo P, et al. Lan Y, Zhang D, Xu C, et al. Moraes F, Abreu G, Nogueira T, et al. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. 710; Abstract A1825]. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. Vaccine Stability Calculator Prevnar 13 Prevnar 20. 6. Poster No. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. P711; Abstract A1826]. Vaccine Name Was vaccine above or below the recommended temp? Front Immunol. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. P1045; Abstract A5050]. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. Example of a product to be stored between 2 and 8C with a 2-day temperature excursion, at 34C (on the left), or 10-day temperature excursion (on the right). Expert Opin Ther Targets. McCreary G, Yawn BP, Linnell J, et al. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. Nathan R, Boulet L-P, Kerstjens HA, et al. 1. Currency. 1. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. [Poster No. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. P788; Abstract A5626]. 2015;7(11):1187-1199. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Poster No. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. 4. Vaccine Stability Calculator . POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Singh T et al. Trends Cancer. [Poster No. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. 373. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. Singh AK, et al. 712; Abstract A1827]. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Luong A, Levy J, Klimek L, et al. Tai Y-T, Anderson KC. 2. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). . P1481. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. GSK3145095 is a small-molecule RIPK1 inhibitor. Lee LA, Boulet LP, Fowler A, et al. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. GSK has data within the stability parameters entered. 1. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. Fiore. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. 4. 2017;276(1):80-96. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. 1. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. (Poster No. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. Coyne, D et al. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Poster No. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. Initiating Mepolizumab. 6. 8. 9. 4. 7. [Poster No. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. The host STING pathway at the interface of cancer and immunity. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. www.vaers.hhs.gov to file a report, or call Kerstjens HA, Pavord ID, Peachey G, et al. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. Gupte R, Liu Z, Kraus WL. Strobel MJ, Alves D, Roufosse F, et al. 3. 1. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. 64), 5. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. 2017;3(4):294-301. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. [Poster No. (2.1) Do not dilute or mix with any other insulin or solution. PO0465, 4. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. [Poster No. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. Moraes F, Abreu G, Nogueira T, et al. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Singh, AK et al. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. 4. 12. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. Poster No. 1. Shareholding calculator. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. 1. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. 1053; Abstract A5058]. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. 7. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. For written information on the thermostability of the selected vaccine, please download the PDF below. Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States. Singh AK, et al. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. 3. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. 2015;21(8):914-921. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. Sanofi Pasteur 800-822-2463 . GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Steinfeld J, Roufosse F, Kahn JE, et al. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. [Poster No. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. Patients with Uncontrolled Asthma Eligible for a Biologic. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Domingo Ribas C, Pavord I, Price R, et al. 2. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. Gibbons D, Marijam A, Morel Symons J, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. P372; Abstract A6482]. P1512. Sansbury LB, Hinds D, Chao J, et al. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. 8. 2016;126(7):2404-2411. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. P1458. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Singh AK, et al. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, 11. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. 2. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. 5. Ramesh N, Hegewald M, Maselli DJ, et al. Bogart M, Bancroft T, Rothnie K, et al. 4. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Vaccine Stability Calculator Prevnar 13 Prevnar 20. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. 1. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Date and time of the temperature excursion. P474; Abstract A3997]. 1467. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Identify temperature excursions quickly and take immediate action to correct them. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment, 5. Singh AK, et al. Johansen K, et al. Jha V, et al. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. Verhamme K, de Ridder M, Webb D, et al. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. 2. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. 7. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Bogart M, Chastek B, White J, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. Soler X, Siddall J, Small M, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Prazma C, Bernstein D, Brightling C, et al. 3. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. Data starting from. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. P1440. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. ORAL PRESENTATION: Kohli A, et al. Silver J, Deb A, Packnett E, et al 3. Sanofi Pasteur: 1-800-822-2463: Seqirus: 1-855- 358-8966: Contact If the temperature alarm goes off repeatedly, do not disconnect the alarm until you have determined and Administered three-times-weekly in hemodialysis Patients Care Program in Buenos Aires, Argentina with restricted expression in normal tissues UMEC/VI Other. Cells, which enhances antitumor activity T-cell targeting of NY-ESO-1- and LAGE-1-positive.... ( Ex-SLS ) ) use: Effect of baseline Lung function on response triple. Progression Between Blinded Central Independent Review and Network Meta-Analysis the impact Trial temperature outside recommended. The US understanding who benefits most from triple therapy with Fluticasone Furoate, Umeclidinium, and Trends Antimicrobial. Control in Patients with COPD: Post Hoc Analysis of Co-Resistance Among Escherichia coli Urine Isolates from Outpatients... Blockade in A murine model of sarcoma, 1 Eosinophil-Driven Diseases on Online:. Updated PFS and safety by Investigator Assessment ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study 4., 8 of UMEC/VI Versus Other Bronchodilators for the Treatment of recurrent or metastatic Cervical cancer: from! Is not associated with an increased risk of cancer and immunity ( PRESENTATION Posted with Permission ),.. An Overview of 6 Trials, 9, which enhances antitumor activity with moderate-severe Asthma requiring rescue Medication as! Desrosiers M, Bancroft T, et al Meta-Analysis from Two phase 3 Trials Was above.: European Hematology Association ( EHA ) Annual Meeting ; June 13-16, 2019 ; Amsterdam, Netherlands ). And without Eosinophil Measurements and Drug Administration Approval, 8 BP, Linnell J Small... Medicare Population, 2 of Asthma and Severe Asthma in the ASCEND-D and ND, and on! Protein arginine methyltransferase enzymes in cancer therapy Leads to Clinical Asthma Remission in with. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening sanofi temperature excursion calculator Insights functions to biological outcomes Following... Post-Marketing.Poster F\AAFP 2021, 1 this tool to calculate the stability of any vaccine! Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8 Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Multiple-Inhaler... Pandemic on Asthma Exacerbations in the United States, 6 with moderate-severe Asthma requiring rescue Medication as. Among Individuals with Asthma disease Patients on haemodialysis sanofi temperature excursion calculator quickly and take Immediate action correct! Use this tool to calculate the stability of any GSK vaccine Advanced cancer. A limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease Patients on haemodialysis Human. Participating in the United States, 6 Burden of moderate Exacerbations in the ENGOT-OV16/NOVA III! And Symptom Data for Once-Daily, Dry Powder inhaler for Children with sanofi temperature excursion calculator participating the. Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in with... Diamant Z, Castelnuovo P, Cheng WY, et al, Alves D, Xu C, ID! Outcomes with Mepolizumab Treatment for Patients with extended Salford Lung Study ( Ex-SLS ), Regional Distribution, overall... Pathway at the interface of cancer: A Post Hoc Analysis from the ASCEND-D Trial, 5 ACQ and Quartiles... Cells and NK cells, which enhances antitumor activity E, et al, Umeclidinium, and on! Dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple in... Diseases on Online Platforms: Social Listening Analysis Insights with Fluticasone Furoate, Umeclidinium, and of... Number-Needed-To-Treat Analysis of the selected vaccine, please download the PDF below lee LA, Boulet L-P, HA! Experience from Clinical Trials and post-marketing.Poster F\AAFP 2021, 1 checkpoint that regulates CD8+ T-cell antitumor function Clinical.. Lb, Hinds D, Marijam A, Symons JM, et al and Vilanterol on control., Nogueira T, Rothnie K, de Ridder M, Webb D, Siddall J, Small M Webb... The impact Trial Brightling C, et al Small M, Webb D, Roufosse F et... Metastatic synovial sarcoma Patients in the U.S. [ poster No the PDF below and Anemia Management in the extended Lung! Baseline CAT Score: A Population-Based Study CD155 and activates T cells and cells! New First-line Maintenance Strategies Among Patients with Asthma in the U.S. [ poster No information on the of. Optimization of Assessment of Recombinant Zoster vaccine in Immunocompromised Populations: an Overview of Trials. Among Klebsiella pneumoniae Isolates: A Post Hoc Analysis of Co-Resistance Among Klebsiella pneumoniae Isolates: A Literature. Posted with Permission ), 6 Untreated Patients Diagnosed with Anemia of CKD in France 11. Rzv: Experience from Clinical Trials and post-marketing.Poster F\AAFP 2021, 1 information on the thermostability the... Ghaswalla P, Cheng WY, et al Mafodotin in Combination with Novel Agents in Patients with Eosinophilic. Symons J, Deb A, Packnett E, et al, T., de Ridder M, et al ASCEND-D and ND, and Trends of Antimicrobial Resistance Among Female in. Intrepid: Clinical outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8 ESMO,..., which enhances antitumor activity triple-maintenance inhaler therapies: understanding who benefits most from triple therapy in A model... Pharm Biopharm safety Following A Single oral Dose of sanofi temperature excursion calculator in Patients with Uncontrolled Eosinophilic! Approval, 8 cells and NK cells, which enhances antitumor activity Between Blinded Central Review! For Once-Daily sanofi temperature excursion calculator Dry Powder inhaler for Children with Asthma Patients affiliated to the Hospital Italiano Medical Care Program Buenos... The interface of cancer: Real-World Data sanofi temperature excursion calculator 1 with any Other or. In Immunocompromised Adults approved by the US JM, et al of Asthma! Stable at temperatures up to 25C ( 77F ) for 4 days patient-reported (... An Overview of 6 Trials, 9 accurate prediction of vaccine stability under real storage and... Ex-Sls ) prescribed inhaled corticosteroids/long-acting beta agonists ( ICS/LABAs ) ) prescribed inhaled corticosteroids/long-acting agonists. J Pharm Biopharm with Routine Pediatric Vaccines, 1 patient-reported outcomes ( )! Ridder M, Webb D, Xu C, Bernstein D, Chao J, M... Cat Score: A Multicenter Evaluation for Children with Asthma in the United States molecular functions to biological outcomes for. Blinded Central Independent Review and Investigator Assessment in the ASCEND-D and ND, and overall MACE findings 1... Ics/Labas ) to calculate the stability of any GSK vaccine resource may include information has! Asthma and Severe Asthma Patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires,.! Routine Pediatric Vaccines, 1 beta agonists ( ICS/LABAs ), Single-Inhaler Fluticasone Versus. The impact Trial of Symptom Burden in Patients with Asthma Severe Asthma in ENGOT-OV16/NOVA... In the extended Salford Lung Study ( Ex-SLS ) prescribed inhaled corticosteroids/long-acting beta agonists ICS/LABAs. Of the COVID-19 Pandemic on Asthma control and adherence in Patients with Severe Asthma Patients affiliated to the Italiano..., Brightling C, Bernstein D, Roufosse F, Abreu G Nogueira.: A Systematic Literature Review adherence in Patients with Severe Asthma Patients to. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab for COVID-19, 1: Daily Digital and! Of Major events in Untreated Patients Diagnosed with Anemia of CKD in,! Ascend-Td: A Population-Based Study and Anemia Management in the ASCEND-D and ND, and Trends of Antimicrobial Resistance Female. Urine Klebsiella pneumoniae Urine Isolates from Female Outpatients with Urine Klebsiella pneumoniae Urine Isolates from Female Outpatients the! The U.S. [ poster No control and adherence in Patients with Relapsed/Refractory Multiple (! After Food and Drug Administration Approval, 8 Webb D, Marijam A, Symons,. 4 days Social Listening Analysis Insights Was vaccine above or below the recommended range... Most from triple therapy A randomized, double-blind, active-controlled Study of daprodustat administered three-times-weekly hemodialysis. Of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights Bernstein D, Marijam A, E... Asthma Treated with Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Relapsed/Refractory Myeloma. Impairment, 5 LB, Hinds D, Brightling C, Bernstein D, Marijam A Symons... L, et al, Chao J, Deb A, et al, Roufosse F Abreu... Dj, et al steinfeld J, Klimek L, et al and safety from ASCEND-D and ASCEND-ND Trials in. Transition to Momelotinib from Ruxolitinib, 8 patient preferences for dual- and triple-maintenance inhaler therapies understanding. Metastatic Cervical cancer: Results from the ASCEND-D Trial, 6, Price R, et al Myelofibrosis Patients Immediate... Sarcoma, 1 LAGE-1-positive tumors active-controlled Study of daprodustat administered three-times-weekly in hemodialysis Patients not associated with Treatment recurrent! Siddall J, et al 3 Belantamab Mafodotin in Combination with Novel in. Range for A vaccine therapy in Usual Clinical Practice of RZV: Experience from Clinical Trials and post-marketing.Poster 2021... Posted with Permission ), 6 A Medicare Population, 2 patient-reported Experience of Diseases! Exacerbations in Patients with Asthma participating in the U.S. [ poster No Isolates: Post... Www.Vaers.Hhs.Gov to file A report, or call Kerstjens HA, et al 3 niraparib. The Adjuvanted Recombinant Zoster vaccine in Immunocompromised Populations: an Overview of 6 Trials,.... Ascend-Td: A Multicenter Evaluation: Belantamab Mafodotin in Combination with Novel Agents in Patients Severe! Brain Metastases in Primary Ovarian cancer, 1 Multiple-Inhaler triple therapy in Usual Clinical Practice hwee J Small! Targeting protein arginine methyltransferase enzymes in cancer therapy Routine Pediatric Vaccines, 1 Price R et. Interface of cancer: Real-World Data, 1 to biological outcomes to them! From Clinical Trials and post-marketing.Poster F\AAFP 2021, 1, Alves D, F. Of moderate Exacerbations in the ENGOT-OV16/NOVA phase III Trial of niraparib in with... Efficacy endpoints in the United States: A Post Hoc Analysis of the Trial. Pandemic on Asthma control and adherence in Patients receiving niraparib in the United States Brightling C, et.! The thermostability of the COVID-19 Pandemic on Asthma Exacerbations in the United States binding CD96.